{"id":"W2729141564","doi":"10.1093/annonc/mdx289","title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":272,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital","funders":"Bayer HealthCare; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Medicine; Internal medicine; Neutropenia; Lymphoma; Gastroenterology; Aggressive lymphoma; Follicular lymphoma; Adverse effect; Rituximab; Phases of clinical research; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005114001,0.0002214214,0.0005944613,0.0001222252,0.0001344843,0.00001099171,0.0006434951,0.0003655475,0.00006985218],"category_scores_gemma":[0.001241092,0.0001776671,0.00009973533,0.00008749493,0.000302304,0.00001004306,0.0004312345,0.0001336113,0.000002937211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004460731,"about_ca_system_score_gemma":0.0008804094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003202435,"about_ca_topic_score_gemma":0.0013207,"domain_scores_codex":[0.9980921,0.0002205652,0.0006590184,0.0004641726,0.0002220445,0.0003421517],"domain_scores_gemma":[0.9971948,0.0000838065,0.001373916,0.000921583,0.0003282344,0.00009770126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03184612,0.0303951,0.006522547,0.0001285479,0.0005713442,0.000816945,0.003334463,0.00005436516,0.6056654,0.00001713491,0.02081441,0.2998336],"study_design_scores_gemma":[0.03881145,0.2496715,0.00598434,0.0003001803,0.00007476591,0.00005727504,0.001290957,0.00002452969,0.6320975,0.00005448844,0.07115529,0.0004776682],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971429,0.000685451,0.000004966678,0.0003133427,0.0004728061,0.0004635513,0.00005285812,0.000006472259,0.0008576554],"genre_scores_gemma":[0.9983751,0.0004338659,0.00009704137,0.0003096824,0.0002513051,0.00007659811,0.00001798589,0.00002882967,0.0004096465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2993559,"threshold_uncertainty_score":0.7245055,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09953814874158444,"score_gpt":0.4373143449775114,"score_spread":0.3377761962359269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}